Introduction In the past decade, antimicrobial resistance (AMR), or a lack of response to traditional antibiotics, has been on the rise. In response, major health organizations such as the World Health Organization (WHO) have declared it one of the top ten threats to global health.1 At the same time, the drug delivery industry has been slow to deliver new antibiotics, especially ones with new mechanisms of action, or ones to which the build-up of AMR is expected to be comparatively slow.